Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been shown to both lower blood pressure and promote weight loss, and they act rather subtly, stated Rudolf de Boer, MD, PhD, clinical cardiologist and professor of translational cardiology, University Medical Center Groningen, the Netherlands.
Among the beneficial effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors are their ability to lower blood pressure and promote weight loss, with newer lab-based studies showing their ability to normalize metabolic abnormalities, stated Rudolf de Boer, MD, PhD, clinical cardiologist and professor of translational cardiology, University Medical Center Groningen, the Netherlands.
Transcript
Why have SGLT2 inhibitors seen such success across several disease states, in particular heart failure, type 2 diabetes, and chronic kidney disease?
That’s an interesting question. We're still not fully aware of how exactly the drugs exert their beneficial effects. On the other hand, it's not so uncommon for cardiovascular drugs to be beneficial in heart disease, in renal disease, and in diabetes. We, of course, are seeing similar trends with RAAS [renin-angiotensin-aldosterone system] inhibitors, the ACE [angiotensin-converting enzyme] inhibitors, the ARBs [angiotensin receptor blockers], the mineralocorticoid receptor antagonists. Also, for example, lipid-lowering drugs, such as statins, have been proven beneficial in patients who are at risk for heart disease, who have prevalent heart disease, patients with diabetes. Clearly, several pathomechanisms are shared when it comes to heart disease, renal disease, and diabetes.
In more detail, we know that SGLT2 inhibitors exert various effects, including blood pressure–lowering effects. Although they're not strong antihypertensives, they do lower blood pressure. They are associated with weight loss— not dramatic weight loss, but on average patients lose several kilograms—and, more recently, there's also been mechanistic studies in the laboratory setting showing that they have certain beneficial effects.
For example, organ metabolism, where they normalize metabolic abnormalities that are common in heart and kidney disease. They, for example, foster the utilization of certain substrates, including ketones and other substrates, where there are shifts in the disease toward certain substrates that necessarily aren't beneficial—so they are normalized by the use of SGLT2 inhibitors.
I think these are very elegant drugs. They don't push particularly hard on one disease mechanism going wrong. What they do is they normalize a number of parameters in a rather subtle manner, and I think that explains their clear efficacy on one side but also their very favorable safety profile on the other hand.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen